As if to highlight the need for speed in the midstage race in alopecia areata (AA, or hair loss in patches), Wayne, Pa.-based Aclaris Therapeutics Inc. in July gained fast track status from the FDA for the phase II topical JAK1/3 inhibitor ATI-502.